Effects of extended lamivudine therapy in asian patients with chronic hepatitis B

Yun Fan Liaw, Nancy W.Y. Leung, Ting Tsung Chang, Richard Guan, Dar In Tai, Keng Yeen Ng, Rong Nan Chien, Julie Dent, Lise Roman, Sally Edmundson, Ching Lung Lai

研究成果: Article同行評審

714 引文 斯高帕斯(Scopus)


Background and Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown. Methods: A total of 334 Asian patients with chronic hepatitis B from a previously reported 1-year study were randomized to receive either lamivudine (100 or 25 mg) or placebo for another year. The effects of treatment on serum HBV-DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion were measured. The presence of YMDD variant HBV and its effect were also determined. Results: A significantly greater proportion of patients achieved sustained HBV-DNA suppression and ALT normalization with 100 mg lamivudine daily for 2 years compared with lamivudine for 1 year followed by placebo for the second year (P < 0.001). Daily lamivudine therapy for 2 years was safe and resulted in incremental HBeAg seroconversion from 17% at week 52 to 27% at week 104. HBeAg seroconversion during continued lamivudine therapy increased linearly with increasing pretherapy ALT levels (P < 0.001). Despite the emergence of YMDD mutant in 38% of the patients, they continued to clear rum HBeAg and maintain lower median serum HBV-DNA and ALT levels than baseline values. In contrast, ALT levels increased 8-12 weeks after switching from lamivudine to placebo, but returned to normal once lamivudine treatment was resumed. Conclusions: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B.

頁(從 - 到)172-180
出版狀態Published - 2000 7月

All Science Journal Classification (ASJC) codes

  • 肝病
  • 消化內科


深入研究「Effects of extended lamivudine therapy in asian patients with chronic hepatitis B」主題。共同形成了獨特的指紋。